---
provider: falcon
model: Edison Scientific Literature
cached: false
start_time: '2026-06-13T06:11:37.901669'
end_time: '2026-06-13T06:18:33.688681'
duration_seconds: 415.79
template_file: templates/gene_research_go_focused.md
template_variables:
  organism: human
  gene_id: FBXO6
  gene_symbol: FBXO6
  uniprot_accession: Q9NRD1
  protein_description: 'RecName: Full=F-box only protein 6; AltName: Full=F-box protein
    that recognizes sugar chains 2; AltName: Full=F-box/G-domain protein 2;'
  gene_info: Name=FBXO6; Synonyms=FBG2, FBS2, FBX6;
  organism_full: Homo sapiens (Human).
  protein_family: Not specified in UniProt
  protein_domains: F-box-assoc_dom. (IPR007397); F-box-like_dom_sf. (IPR036047); F-box_dom.
    (IPR001810); F-box_only. (IPR039752); Galactose-bd-like_sf. (IPR008979)
provider_config:
  timeout: null
  max_retries: 3
  parameters:
    allowed_domains: []
    temperature: 0.1
    max_embedded_images: 8
citation_count: 17
artifact_count: 1
artifact_sources:
  edison_answer_artifacts: 1
artifacts:
- filename: artifact-00.md
  path: FBXO6-deep-research-falcon_artifacts/artifact-00.md
  media_type: text/markdown
  source: edison_answer_artifacts
  data_storage_id: null
  description: Edison artifact artifact-00
---

## Question

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9NRD1
- **Protein Description:** RecName: Full=F-box only protein 6; AltName: Full=F-box protein that recognizes sugar chains 2; AltName: Full=F-box/G-domain protein 2;
- **Gene Information:** Name=FBXO6; Synonyms=FBG2, FBS2, FBX6;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** F-box-assoc_dom. (IPR007397); F-box-like_dom_sf. (IPR036047); F-box_dom. (IPR001810); F-box_only. (IPR039752); Galactose-bd-like_sf. (IPR008979)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "FBXO6" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'FBXO6' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **FBXO6** (gene ID: FBXO6, UniProt: Q9NRD1) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

## Output

Question: You are an expert researcher providing comprehensive, well-cited information.

Provide detailed information focusing on:
1. Key concepts and definitions with current understanding
2. Recent developments and latest research (prioritize 2023-2024 sources)
3. Current applications and real-world implementations
4. Expert opinions and analysis from authoritative sources
5. Relevant statistics and data from recent studies

Format as a comprehensive research report with proper citations. Include URLs and publication dates where available.
Always prioritize recent, authoritative sources and provide specific citations for all major claims.

# Gene Research for Functional Annotation

## ⚠️ CRITICAL: Gene/Protein Identification Context

**BEFORE YOU BEGIN RESEARCH:** You MUST verify you are researching the CORRECT gene/protein. Gene symbols can be ambiguous, especially for less well-characterized genes from non-model organisms.

### Target Gene/Protein Identity (from UniProt):
- **UniProt Accession:** Q9NRD1
- **Protein Description:** RecName: Full=F-box only protein 6; AltName: Full=F-box protein that recognizes sugar chains 2; AltName: Full=F-box/G-domain protein 2;
- **Gene Information:** Name=FBXO6; Synonyms=FBG2, FBS2, FBX6;
- **Organism (full):** Homo sapiens (Human).
- **Protein Family:** Not specified in UniProt
- **Key Domains:** F-box-assoc_dom. (IPR007397); F-box-like_dom_sf. (IPR036047); F-box_dom. (IPR001810); F-box_only. (IPR039752); Galactose-bd-like_sf. (IPR008979)

### MANDATORY VERIFICATION STEPS:

1. **Check if the gene symbol "FBXO6" matches the protein description above**
2. **Verify the organism is correct:** Homo sapiens (Human).
3. **Check if protein family/domains align with what you find in literature**
4. **If you find literature for a DIFFERENT gene with the same or similar symbol, STOP**

### If Gene Symbol is Ambiguous or You Cannot Find Relevant Literature:

**DO NOT PROCEED WITH RESEARCH ON A DIFFERENT GENE.** Instead:
- State clearly: "The gene symbol 'FBXO6' is ambiguous or literature is limited for this specific protein"
- Explain what you found (e.g., "Found extensive literature on a different gene with the same symbol in a different organism")
- Describe the protein based ONLY on the UniProt information provided above
- Suggest that the protein function can be inferred from domain/family information

### Research Target:

Please provide a comprehensive research report on the gene **FBXO6** (gene ID: FBXO6, UniProt: Q9NRD1) in human.

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

# Research Report: Functional Annotation of Human **FBXO6** (UniProt **Q9NRD1**; synonyms **FBS2/FBG2/FBX6**)

## 0) Gene/protein identity verification (critical)
The literature retrieved in this run consistently treats **FBS2 as the official gene/protein name FBXO6** and describes it as an **F-box protein that recognizes sugar chains** and functions within an **SCF (SKP1–CUL1–F-box) E3 ubiquitin ligase** context, matching the UniProt identity for **human FBXO6/Q9NRD1** (F-box domain plus sugar-binding/galactose-binding-like superfamily features). (fujihira2022physiologicalimportanceof pages 4-5, fujihira2022physiologicalimportanceof pages 9-10)

## 1) Key concepts and definitions (current understanding)

### 1.1 FBXO6 as an SCF E3 ligase substrate receptor
FBXO6 (FBS2) is discussed as an F-box protein that serves as the substrate-recognition module of an SCF-type ubiquitin ligase (**SCF^FBS2 / SCF^FBXO6**), enabling ubiquitination of selected substrates, including **N-glycoproteins** involved in protein quality control. (fujihira2022physiologicalimportanceof pages 9-10, fujihira2022physiologicalimportanceof pages 28-29)

### 1.2 FBXO6 in ER-associated degradation (ERAD) and glycoproteostasis
ER-associated degradation (ERAD) eliminates misfolded secretory-pathway proteins, often glycoproteins, by **retrotranslocation to the cytosol**, **ubiquitination**, and **proteasomal degradation**. In the NGLY1/ERAD axis summarized in a 2022 review, ERAD glycoprotein substrates (including the transcription factor **NFE2L1/NRF1**) are ubiquitinated by multiple E3 ligases, including **SCF^FBS2**, and then degraded by the proteasome; in typical conditions, many ubiquitinated glycoproteins are thought to be **deglycosylated by NGLY1 during proteasomal degradation**. (fujihira2022physiologicalimportanceof pages 28-29)

### 1.3 Relationship to NGLY1 deficiency and proteasome homeostasis
NFE2L1 is central to the “proteasome bounce-back response” (induction of proteasome subunits under proteotoxic stress). In the cited mechanistic model, **SCF^FBS2 ubiquitinates NFE2L1**, and in the **absence of NGLY1**, SCF^FBS2-mediated ubiquitination of NFE2L1 is linked to impaired NFE2L1 processing/nuclear function and failure to induce proteasome subunits, contributing to chronic proteasome compromise and cytotoxicity. (fujihira2022physiologicalimportanceof pages 9-10, fujihira2022physiologicalimportanceof pages 28-29)

## 2) Molecular function, specificity, partners, localization (evidence-based)

### 2.1 Molecular function: ubiquitination (E3 ligase adaptor/substrate receptor)
Across the mechanistic sources retrieved here, the primary experimentally anchored molecular role for FBXO6 is as part of **SCF^FBS2** that mediates ubiquitination of **N-glycoprotein substrates** (including NFE2L1 in the NGLY1-deficiency context). (fujihira2022physiologicalimportanceof pages 9-10, fujihira2022physiologicalimportanceof pages 28-29)

### 2.2 Substrate scope supported in retrieved evidence
The most specific substrate explicitly discussed in the retrieved evidence is **NFE2L1**, described as ubiquitinated by SCF^FBS2 and functionally impacted in NGLY1-deficient states. (fujihira2022physiologicalimportanceof pages 9-10, fujihira2022physiologicalimportanceof pages 28-29)

The same review framing also refers broadly to “ERAD substrate glycoproteins” being ubiquitinated by SCF^FBS2, without naming additional specific protein substrates in the excerpts available here. (fujihira2022physiologicalimportanceof pages 28-29)

### 2.3 Sugar-chain recognition / lectin-like specificity
Within the full text inspected, FBXO6/FBS2 is repeatedly described at a high level as **“an F-box protein that recognizes sugar chains”**, consistent with UniProt’s alternative name “F-box protein that recognizes sugar chains 2.” (fujihira2022physiologicalimportanceof pages 4-5)

However, in the tool-retrieved excerpts available for this run, **detailed biochemical specificity (e.g., high-mannose vs other N-glycan structures), structural determinants, and exact domain-function mapping** (e.g., which residues mediate glycan binding) are **not provided**. (fujihira2022physiologicalimportanceof pages 9-10, fujihira2022physiologicalimportanceof pages 28-29)

### 2.4 Cellular localization and site of action
The mechanistic model places SCF^FBS2 activity in the **cytosolic/proteasomal degradation pathway for ERAD substrates** (i.e., after retrotranslocation from the ER lumen), and describes **accumulation of SCF^FBS2-ubiquitinated N-glycoproteins in the cytosol** when NGLY1 is absent. (fujihira2022physiologicalimportanceof pages 9-10, fujihira2022physiologicalimportanceof pages 28-29)

The excerpts retrieved here do not provide direct microscopy-based subcellular localization of FBXO6 itself (e.g., ER membrane association vs cytosolic distribution) or compartment-specific enrichment; thus, localization is inferred from the ERAD/proteasome context discussed rather than directly demonstrated in the excerpts available in this run. (fujihira2022physiologicalimportanceof pages 9-10, fujihira2022physiologicalimportanceof pages 28-29)

## 3) Recent developments (prioritizing 2023–2024)

### 3.1 2023: FBXO6 included in an ER-stress prognostic signature in breast cancer (TCGA-BRCA)
A 2023 study in *Frontiers in Oncology* (published **May 2023**) developed and validated an endoplasmic reticulum stress-related prognostic model (“**ERScore**”) for breast cancer. In that work, **FBXO6** was one of **four genes** (FBXO6, PMAIP1, ERP27, CHAC1) identified by multivariate Cox analysis as **independent prognostic factors**. (fan2023developmentandvalidation pages 1-2)

The authors also performed **protein-level validation by Western blot**, reporting that FBXO6 protein expression was **higher in breast cancer cell lines** (SKBR-3, MDA-MB-231, T-47D) than in the normal mammary epithelial line MCF-10A; they further report that **FBXO6 expression did not significantly differ with breast cancer stage**. Publication URL: https://doi.org/10.3389/fonc.2023.1178595 (fan2023developmentandvalidation pages 3-5, fan2023developmentandvalidation pages 17-18)

**Quantitative data reported in the retrieved excerpts:** the study evaluated drug sensitivity differences and found that **43 of 138 drugs** showed significant differences between the high- and low-ERScore groups (and noted greater sensitivity to 8 drugs in the low-ERScore group). These are ERScore-level statistics rather than FBXO6-specific effect sizes. (fan2023developmentandvalidation pages 10-11)

### 3.2 2024: FBXO6 included in an FBXO-family prognostic model in hepatocellular carcinoma (HCC)
A 2024 paper in *Journal of Cancer Research and Clinical Oncology* (published **Oct 2024**) built a six-gene prognostic model for HCC from FBXO family members (FBXO5, **FBXO6**, FBXO16, FBXO30, FBXO32, FBXO45). Publication URL: https://doi.org/10.1007/s00432-024-05948-3 (gong2024fbxofamilygenes pages 11-14, gong2024fbxofamilygenes pages 7-11)

**Key quantitative performance statistics reported:** ROC AUC values for the model were **0.744**, **0.670**, and **0.638** at **1**, **3**, and **5** years, respectively. (gong2024fbxofamilygenes pages 11-14)

**Experimental validation reported:** the study used **immunohistochemistry (IHC)** and states that model genes (including FBXO6) showed higher expression in tumor vs adjacent tissue, including mention of higher expression of **FBXO6** in invasive tumor specimens. (gong2024fbxofamilygenes pages 11-14)

**Important limitation/expert-style interpretation:** despite framing around p53 ubiquitination, the paper explicitly acknowledges that it **did not elucidate specific molecular mechanisms of FBXO proteins in HCC** and that lack of experimental verification is a limitation; the p53 connection for FBXO6 in this paper is primarily supported by **bioinformatic prediction/docking** rather than direct ubiquitination assays. (gong2024fbxofamilygenes pages 16-17)

## 4) Current applications and real-world implementations

### 4.1 Translational concept: FBXO6 inhibition as a potential strategy in NGLY1 deficiency (preclinical rationale)
Rodent model synthesis indicates that **genetic reduction of FBS2/FBXO6** can partially rescue lethality/phenotypes associated with **Ngly1 knockout**, and that **Fbs2 knockout mice are reported as healthy** in that review context. This leads the authors to propose that **FBS2 inhibition** might be a promising therapeutic concept with potentially low side effects for **NGLY1 deficiency** (an ultra-rare congenital disorder of deglycosylation). (fujihira2022physiologicalimportanceof pages 9-10)

This is not a clinical implementation; rather, it represents a mechanistically motivated preclinical target rationale grounded in mouse genetics and proteostasis pathway logic. (fujihira2022physiologicalimportanceof pages 9-10)

### 4.2 Oncology: biomarker/model-gene usage in prognostic signatures
Two recent studies implement FBXO6 as a component of computational/omics-driven prognostic models:
- **Breast cancer ER stress ERScore model** with Western blot validation in cell lines (May 2023). (fan2023developmentandvalidation pages 1-2, fan2023developmentandvalidation pages 3-5)
- **HCC FBXO-family model** with IHC expression validation and time-dependent AUCs (Oct 2024). (gong2024fbxofamilygenes pages 11-14)

These implementations are “real-world” in the sense of research/clinical bioinformatics workflows, but they are not yet established clinical tests.

## 5) Expert opinions and authoritative analysis (from retrieved sources)

### 5.1 Proteostasis-centered interpretation (review-level synthesis)
The NGLY1 rodent model review highlights a mechanistic link between **SCF^FBS2-mediated ubiquitination of glycoproteins (including NFE2L1)** and **proteasome dysfunction** in NGLY1-deficient settings, framing FBXO6/FBS2 as a meaningful node connecting ERAD substrate handling, deglycosylation status, and proteasome homeostatic responses. (fujihira2022physiologicalimportanceof pages 9-10, fujihira2022physiologicalimportanceof pages 28-29)

### 5.2 Caution on disease-mechanism claims from association studies
The 2024 HCC prognostic-model paper’s own text explicitly flags missing experimental verification of proposed mechanisms (including p53-related ubiquitination), underscoring that some FBXO6 disease-mechanism claims in cancer contexts remain **hypothesis-generating** rather than definitive. (gong2024fbxofamilygenes pages 16-17)

## 6) Relevant statistics and data (from recent studies)

- **Breast cancer (Frontiers in Oncology, May 2023):** drug-sensitivity comparison between ERScore strata reported **43/138 drugs** with significant differences (ERScore-level statistic). URL: https://doi.org/10.3389/fonc.2023.1178595 (fan2023developmentandvalidation pages 10-11)
- **HCC (J Cancer Res Clin Oncol, Oct 2024):** six-gene prognostic model time-dependent ROC AUCs of **0.744 (1y)**, **0.670 (3y)**, **0.638 (5y)**. URL: https://doi.org/10.1007/s00432-024-05948-3 (gong2024fbxofamilygenes pages 11-14)
- **NGLY1 deficiency modifier genetics (reviewed, Sep 2022):** **50% genetic reduction** of FBS2 reported to partially rescue Ngly1-KO lethality; Fbs2-KO mice described as healthy in that synthesis. URL: https://doi.org/10.1093/jb/mvab101 (fujihira2022physiologicalimportanceof pages 9-10)

## 7) Summary of evidence-backed functional annotation

| Functional aspect | Key findings | Evidence type | System/Context | Citation ID(s) |
|---|---|---|---|---|
| SCF substrate receptor in glycoprotein quality control | FBXO6/FBS2 is described as part of an SCF ubiquitin ligase that ubiquitinates N-glycoproteins and participates in glycoprotein quality control linked to ER-associated degradation. | Review synthesis of prior biochemical/cell studies | NGLY1/ERAD pathway | (fujihira2022physiologicalimportanceof pages 9-10, fujihira2022physiologicalimportanceof pages 28-29) |
| ERAD glycoprotein ubiquitination | In NGLY1-deficient settings, SCF^FBS2-ubiquitinated N-glycoproteins accumulate in the cytosol and are associated with impaired proteasomal activity. | Cell-based observations summarized in review | NGLY1-deficient cells/models | (fujihira2022physiologicalimportanceof pages 9-10, fujihira2022physiologicalimportanceof pages 28-29) |
| NFE2L1 regulation | SCF^FBS2 ubiquitinates NFE2L1; in the absence of NGLY1 this impairs NFE2L1 processing/nuclear function and blocks proteasome subunit upregulation under proteotoxic stress. | Review synthesis of mechanistic and cell-based findings | NGLY1 deficiency and proteasome bounce-back pathway | (fujihira2022physiologicalimportanceof pages 9-10, fujihira2022physiologicalimportanceof pages 28-29) |
| Genetic modifier of NGLY1 deficiency | Reducing FBS2 dosage partially rescues lethality in Ngly1-knockout mice; Fbs2 deletion reportedly suppresses Ngly1-KO phenotypes more strongly than Engase deletion, while Fbs2-KO mice are described as otherwise healthy. | Mouse genetics | Rodent NGLY1-deficiency models | (fujihira2022physiologicalimportanceof pages 9-10) |
| Candidate therapeutic target | Because FBS2 loss is phenotypically tolerated in mice and alleviates Ngly1-deficiency phenotypes, reviews suggest FBS2 inhibition as a potential therapeutic strategy for NGLY1 deficiency. | Expert review/analysis grounded in mouse genetics | Translational interpretation of NGLY1-deficiency models | (fujihira2022physiologicalimportanceof pages 9-10) |
| Breast cancer prognostic marker | FBXO6 was one of four independent prognostic factors in an ER stress-related breast cancer model; protein expression was higher in breast cancer cell lines than in MCF-10A by Western blot, and FBXO6 expression reportedly did not significantly vary by stage. | Bioinformatics + Western blot | TCGA-BRCA ERScore model; SKBR-3, MDA-MB-231, T-47D vs MCF-10A | (fan2023developmentandvalidation pages 1-2, fan2023developmentandvalidation pages 3-5, fan2023developmentandvalidation pages 17-18) |
| HCC prognostic/model gene | FBXO6 was included in a six-gene FBXO-family prognostic model for HCC; IHC showed higher expression of model genes in tumor vs adjacent tissue, including higher FBXO6 in invasive tumor specimens. Model AUCs were 0.744, 0.670, and 0.638 at 1, 3, and 5 years. | Bioinformatics + IHC | TCGA-LIHC prognostic model | (gong2024fbxofamilygenes pages 11-14, gong2024fbxofamilygenes pages 7-11, gong2024fbxofamilygenes pages 2-4) |
| HCC mechanism claims in literature vs current paper | The 2024 HCC study cites prior literature that FBXO6 promotes degradation of NLRX1 and Chk1, but its own FBXO6-related mechanistic claims are mainly predictive/associative (e.g., p53 docking/prediction) and the authors acknowledge lack of direct experimental validation. | Literature citation within paper + bioinformatics/IHC in current paper | HCC | (gong2024fbxofamilygenes pages 11-14, gong2024fbxofamilygenes pages 7-11, gong2024fbxofamilygenes pages 16-17) |


*Table: This table summarizes the directly supported functional annotation evidence retrieved for human FBXO6/Q9NRD1, separating mechanistic ERAD/NGLY1 findings from more associative cancer biomarker studies. It is useful for distinguishing well-supported core biology from newer, less validated disease-context observations.*

## 8) Evidence gaps and what could not be confirmed from retrieved full text
1. **Precise glycan-binding specificity** (e.g., defined N-glycan motifs) and **structural mechanism** of sugar recognition by FBXO6 were not available in the retrieved excerpts; therefore, this report does not claim a specific glycan preference beyond “recognizes sugar chains.” (fujihira2022physiologicalimportanceof pages 9-10, fujihira2022physiologicalimportanceof pages 28-29)
2. **Direct subcellular localization data** (immunofluorescence/biochemical fractionation of FBXO6) were not retrieved in the available text excerpts; localization is inferred from ERAD/proteasomal context. (fujihira2022physiologicalimportanceof pages 9-10)
3. **Cancer-mechanism details** for FBXO6 are limited in the retrieved 2023–2024 oncology papers: the breast cancer paper treats FBXO6 primarily as a prognostic-model gene, and the HCC paper explicitly notes lack of mechanistic experimental verification for its proposed p53-ubiquitination framing. (fan2023developmentandvalidation pages 17-18, gong2024fbxofamilygenes pages 16-17)

## Key primary sources used (publication date; URL)
- Fujihira H, Asahina M, Suzuki T. *Journal of Biochemistry* (**Sep 2022**). https://doi.org/10.1093/jb/mvab101 (fujihira2022physiologicalimportanceof pages 9-10, fujihira2022physiologicalimportanceof pages 28-29)
- Fan P et al. *Frontiers in Oncology* (**May 2023**). https://doi.org/10.3389/fonc.2023.1178595 (fan2023developmentandvalidation pages 1-2, fan2023developmentandvalidation pages 3-5, fan2023developmentandvalidation pages 17-18, fan2023developmentandvalidation pages 10-11)
- Gong Q et al. *Journal of Cancer Research and Clinical Oncology* (**Oct 2024**). https://doi.org/10.1007/s00432-024-05948-3 (gong2024fbxofamilygenes pages 11-14, gong2024fbxofamilygenes pages 16-17)

References

1. (fujihira2022physiologicalimportanceof pages 4-5): Haruhiko Fujihira, Makoto Asahina, and Tadashi Suzuki. Physiological importance of ngly1, as revealed by rodent model analyses. Journal of biochemistry, 171:161-167, Sep 2022. URL: https://doi.org/10.1093/jb/mvab101, doi:10.1093/jb/mvab101. This article has 25 citations and is from a peer-reviewed journal.

2. (fujihira2022physiologicalimportanceof pages 9-10): Haruhiko Fujihira, Makoto Asahina, and Tadashi Suzuki. Physiological importance of ngly1, as revealed by rodent model analyses. Journal of biochemistry, 171:161-167, Sep 2022. URL: https://doi.org/10.1093/jb/mvab101, doi:10.1093/jb/mvab101. This article has 25 citations and is from a peer-reviewed journal.

3. (fujihira2022physiologicalimportanceof pages 28-29): Haruhiko Fujihira, Makoto Asahina, and Tadashi Suzuki. Physiological importance of ngly1, as revealed by rodent model analyses. Journal of biochemistry, 171:161-167, Sep 2022. URL: https://doi.org/10.1093/jb/mvab101, doi:10.1093/jb/mvab101. This article has 25 citations and is from a peer-reviewed journal.

4. (fan2023developmentandvalidation pages 1-2): Pengyu Fan, Jiajia Wang, Ruolei Li, Kexin Chang, Liuyin Liu, Yaping Wang, Zhe Wang, Bo Zhang, Cheng Ji, Jian Zhang, Suning Chen, and Rui Ling. Development and validation of an endoplasmic reticulum stress-related molecular prognostic model for breast cancer. Frontiers in Oncology, May 2023. URL: https://doi.org/10.3389/fonc.2023.1178595, doi:10.3389/fonc.2023.1178595. This article has 12 citations.

5. (fan2023developmentandvalidation pages 3-5): Pengyu Fan, Jiajia Wang, Ruolei Li, Kexin Chang, Liuyin Liu, Yaping Wang, Zhe Wang, Bo Zhang, Cheng Ji, Jian Zhang, Suning Chen, and Rui Ling. Development and validation of an endoplasmic reticulum stress-related molecular prognostic model for breast cancer. Frontiers in Oncology, May 2023. URL: https://doi.org/10.3389/fonc.2023.1178595, doi:10.3389/fonc.2023.1178595. This article has 12 citations.

6. (fan2023developmentandvalidation pages 17-18): Pengyu Fan, Jiajia Wang, Ruolei Li, Kexin Chang, Liuyin Liu, Yaping Wang, Zhe Wang, Bo Zhang, Cheng Ji, Jian Zhang, Suning Chen, and Rui Ling. Development and validation of an endoplasmic reticulum stress-related molecular prognostic model for breast cancer. Frontiers in Oncology, May 2023. URL: https://doi.org/10.3389/fonc.2023.1178595, doi:10.3389/fonc.2023.1178595. This article has 12 citations.

7. (fan2023developmentandvalidation pages 10-11): Pengyu Fan, Jiajia Wang, Ruolei Li, Kexin Chang, Liuyin Liu, Yaping Wang, Zhe Wang, Bo Zhang, Cheng Ji, Jian Zhang, Suning Chen, and Rui Ling. Development and validation of an endoplasmic reticulum stress-related molecular prognostic model for breast cancer. Frontiers in Oncology, May 2023. URL: https://doi.org/10.3389/fonc.2023.1178595, doi:10.3389/fonc.2023.1178595. This article has 12 citations.

8. (gong2024fbxofamilygenes pages 11-14): Qingge Gong, La Zhang, Jiao Guo, Wei Zhao, Baoyong Zhou, Changhong Yang, and Ning Jiang. Fbxo family genes promotes hepatocellular carcinoma via ubiquitination of p53. Journal of Cancer Research and Clinical Oncology, Oct 2024. URL: https://doi.org/10.1007/s00432-024-05948-3, doi:10.1007/s00432-024-05948-3. This article has 7 citations and is from a peer-reviewed journal.

9. (gong2024fbxofamilygenes pages 7-11): Qingge Gong, La Zhang, Jiao Guo, Wei Zhao, Baoyong Zhou, Changhong Yang, and Ning Jiang. Fbxo family genes promotes hepatocellular carcinoma via ubiquitination of p53. Journal of Cancer Research and Clinical Oncology, Oct 2024. URL: https://doi.org/10.1007/s00432-024-05948-3, doi:10.1007/s00432-024-05948-3. This article has 7 citations and is from a peer-reviewed journal.

10. (gong2024fbxofamilygenes pages 16-17): Qingge Gong, La Zhang, Jiao Guo, Wei Zhao, Baoyong Zhou, Changhong Yang, and Ning Jiang. Fbxo family genes promotes hepatocellular carcinoma via ubiquitination of p53. Journal of Cancer Research and Clinical Oncology, Oct 2024. URL: https://doi.org/10.1007/s00432-024-05948-3, doi:10.1007/s00432-024-05948-3. This article has 7 citations and is from a peer-reviewed journal.

11. (gong2024fbxofamilygenes pages 2-4): Qingge Gong, La Zhang, Jiao Guo, Wei Zhao, Baoyong Zhou, Changhong Yang, and Ning Jiang. Fbxo family genes promotes hepatocellular carcinoma via ubiquitination of p53. Journal of Cancer Research and Clinical Oncology, Oct 2024. URL: https://doi.org/10.1007/s00432-024-05948-3, doi:10.1007/s00432-024-05948-3. This article has 7 citations and is from a peer-reviewed journal.

## Artifacts

- [Edison artifact artifact-00](FBXO6-deep-research-falcon_artifacts/artifact-00.md)

## Citations

1. fujihira2022physiologicalimportanceof pages 28-29
2. fujihira2022physiologicalimportanceof pages 4-5
3. fan2023developmentandvalidation pages 1-2
4. fan2023developmentandvalidation pages 10-11
5. gong2024fbxofamilygenes pages 11-14
6. gong2024fbxofamilygenes pages 16-17
7. fujihira2022physiologicalimportanceof pages 9-10
8. fan2023developmentandvalidation pages 3-5
9. fan2023developmentandvalidation pages 17-18
10. gong2024fbxofamilygenes pages 7-11
11. gong2024fbxofamilygenes pages 2-4
12. https://doi.org/10.3389/fonc.2023.1178595
13. https://doi.org/10.1007/s00432-024-05948-3
14. https://doi.org/10.1093/jb/mvab101
15. https://doi.org/10.1093/jb/mvab101,
16. https://doi.org/10.3389/fonc.2023.1178595,
17. https://doi.org/10.1007/s00432-024-05948-3,